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Background: Few studies to date have evaluated gastric cancer(GC)-related malignant neoplasm family history
(MN-FH), and their findings have been largely inconsistent. The aim of this study is to evaluate the prevalence of
MN-FH and its relation to the clinicopathologic features of GC.
Methods: A total of 104 hospitalized patients with primary gastric adenocarcinoma was prospectively analyzed
from 2008 to 2009. Positive MN-FH was defined as MN-affected first- and second-degree relatives of the current GC
cases. The relation between prevalence of positive MN-FH and clinicopathologic features in the current GC patients
was assessed using the Chi-square test with Cramer’s V coefficient.
Results: Thirty-seven (35.6%) of the GC patients had positive MN-FH, with 42 associated tumors in first- and
second-degree relatives. Twenty-six (61.9%) of the associated tumors were located in the digestive system,
including the esophagus (26.2%), stomach (23.8%), liver (9.5%) and colon (2.4%). Lung cancers were the most
prevalent non-digestive system-associated tumors (9.5%). Correlation analysis revealed no significant relations
with prevalence of MN-FH and any of the clinicopathologic features (all, P > 0.05), including sex (V = 0.044), age
(V = 0.060) and histological subtypes (V = 0.109).
Conclusions: More than one-third of the GC patients in our hospital had positive MN-FH. The most frequent forms
of MN-FH were esophageal cancer and GC. The prevalence of positive MN-FH was not correlated to any of the
clinicopathologic features, including sex, age and histological subtypes in the study population of GC patients.
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Gastric cancer (GC) is one of the most common malignant
tumors diagnosed worldwide. Although the incidence
of GC in many developed countries has shown a downward
trend over the past decade, over 980,000 new cases
were estimated in 2008 [1], 70% of which occurred in
developing countries. GC is not only the second most
common malignant tumor reported in China [1], but
accounted for more than 460,000 new cases and more
than 350,000 deaths in 2008 alone [2].
The majority of GC cases worldwide are believed to be
sporadic. Only about 10% of GC cases show familial* Correspondence: yujxsd@hotmail.com
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reproduction in any medium, provided the oraggregation, which is defined as two or more GC patients
in close relatives [3]. Furthermore, only 1 to 3% of GC
cases have been diagnosed as hereditary syndromes [4].
Familial gastric cancer (FGC) has been associated with
environmental factors, such as Helicobacter pylori infection
and a high salt diet, and genetic factors, such as E-cadherin
mutations [5,6]; however, it is possible that interactions
between environmental and genetic factors may increase
the risk of FGC or promote its pathogenic progress.
Familial history of malignant neoplasm (MN-FH) has
been characterized as a risk factor of GC, due to the fact
that close family members are often exposed to similar
environmental risk factors and are subject to inherited
genetic susceptibility [7]. However, the exact environmental
and genetic factors differ for families in different areas [8],
creating a regional disparity for MN-FH risk. Therefore,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The location of associated tumors in gastric
cancer patients with positive malignant neoplasm
family history
Associated malignant neoplasm Number Constituent ratio, %
Esophageal carcinoma 11 26.2
Gastric cancer 10 23.8
Liver cancer 4 9.5
Lung cancer 4 9.5
Cervical/endometrial cancer 2 4.8
Colon cancer 1 2.4
Breast cancer 1 2.4
Brain glioma 1 2.4
Nasopharyngeal carcinoma 1 2.4
Eye malignant neoplasm 1 2.4
Uncertain malignant neoplasm 6 14.3
Total 42 100
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and evaluating its relation with the clinicopathologic
features of GC patients may help in designing effective
diagnostic and therapeutic strategies to reduce the number
of cases of GC in high-risk areas, such as in China. Few
studies [9-12] to date have evaluated GC-related MN-
FH, and their findings have been largely inconsistent.
We conducted a study of GC patients in the Shandong
Province of in the north of China to determine if MN-
FH was a risk factor for GC and whether it was related
to any clinicopathologic features of current GC patients.
Methods
A total of 104 patients diagnosed with primary gastric
adenocarcinoma and hospitalized in the Department of
Gastrointestinal Surgery at Liaocheng People’s Hospital
(Shandong, China) from January 2008 to December 2009,
was enrolled in our prospective study. The MN-FH for each
case was determined upon admission by a single investiga-
tor (JXY), who relied on patient self-reporting or reporting
by an accompanying spouse or adult-age child. Positive
MN-FH was defined as malignant neoplasm-affected first-
and second-degree relatives of the current GC case.
The study did not include any intervention beyond
the prescribed treatment regimens and histological types,
(defined by World Health Organization (WHO) standards
[13]), which were obtained from the patient records. The
study was approved by the Ethical Committee of Liaocheng
People’s Hospital.
All statistical analyses were carried out with SAS soft-
ware v9.0 (SAS Institute, Cary, NC, USA). The Chi-square
(χ2) test was used to evaluate the correlation between
MN-FH prevalence and various clinicopathological fea-
tures using the Cramer’s V coefficient. Statistical signifi-
cance was indicated by a P-value less than 0.05.Results
Of the 104 GC cases in this study, 76 were male and 28
were female. The median age was 58 years old (range: 22
to 80 years). Thirty-seven (35.6%) of the GC cases had
positive MN-FH, with 42 associated tumors in first- and
second-degree relatives.
The 42 associated malignant tumors and their frequen-
cies are listed in Table 1. Twenty-six (61.9%) of the as-
sociated tumors were located in the digestive system
(esophagus, stomach, liver and colon). Twenty-two (52.4%)
of the associated tumors were located in the alimentary
tract (esophagus, stomach and colon). The ratios of
esophageal cancer and gastric cancer MN-FH were 26.2%
and 23.8%, respectively. Those cancers very rarely re-
presented by the associated tumors (each 1/42) included
colon, breast, brain, nasopharangeal and ocular.
As shown in Table 2, there were no significant differ-
ences in the MN-FH prevalence among different sexes(V = 0.044), ages (V = 0.060), or histological subtypes (V =
0.109) of the current GC patients (all, P > 0.05).
Discussion
Family history of malignant neoplasm as a risk factor for GC
An earlier large-scale retrospective study [14] had reported
that family history is a sufficiently reliable predictor of
cancer risk for all types of cancers. While our study
was smaller in scale (n = 104) and more focused (all
Chinese from a single region), it was prospective in nature
and, unlike the earlier study, not solely based on a
questionnaire administered by multiple investigators.
The author (JXY) as a single investigator collected data
in-person with the aim of increasing our study’s reliability.
Our results showed 35.6% of 104 patients with GC
presented with MN-FH in first- and second-degree rela-
tives. This percentage is notably lower than that reported
from a study in Japan (46.4%) [11]; however, the higher
GC incidence in Japan may account for the overall higher
MN-FH prevalence. Another study of Italian GC patients
reported MN-FH for 70.8% of the study population [10]. It
is possible that this remarkably high MN-FH may reflect
an ethnicity-related genetic susceptibility. Ten (9.61%)
of the 104 GC patients in our study had one or more
first- and second-degree relatives with GC. This familial
clustering of GC agrees with previous reports stating that
approximately 90% of GC cases are sporadic and only
approximately 10% present familial clustering [3,4].Most MN-FH associated tumors of GC patients were located
in the digestive system, especially in the esophagus and
stomach
Our results showed that more than one-half (61.9%) of
associated tumors in MN-FH were located in the digestive
system. Likewise, a previous study of MN-FH in second-
Table 2 The prevalence of malignant neoplasm family











Cramer’s V χ2 P-
value
Sex 0.044 0.197 0.657
Male 76 28 (36.8)
Female 28 9 (32.1)
Ages, years 0.060 0.368 0.832
<45 22 9 (40.9)
45 to 60 39 13 (33.3)
>60 43 15 (34.9)
Histology
TUBa 19 5 (26.3) 0.109 0.776*
PORb 69 27 (39.1)
SIGc 10 3 (30.0)
MUCd 6 2 (33.3)
*: Fisher's exact test.
aTUB, tubular adenocarcinoma; bPOR, poorly differentiated adenocarcinoma;
cSIG, signet-ring cell carcinoma; dMUC, mucinous adenocarcinoma.
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Province in the south of China determined that 74.9% of
associated tumors were located in the stomach, esopha-
gus, liver and colorectum. A study of MN-FH in Japanese
GC patients also found that 70.9% of total associated
malignant neoplasms involved organs of the digestive
system (stomach, colorectum, liver, esophagus and pan-
creas) [11]. However, the reported prevalence of each
organ-specific MN-FH-associated tumor was different
for different regions. Our study population from north
of China had the highest amount of associated tumors
in the esophagus (26.2%), followed by the stomach
(23.8%). The report cited above, using GC patients from
south of China, found notably different percentages of
stomach- and esophagus-associated tumors (38.6% and
18.3%, respectively) [15]. In contrast, the study of Japanese
GC patients found that 40.9% of associated tumors were
located in the stomach [11], while the study of Italian
GC patients found that only 21.9% of associated tumors
were located in the stomach [10]. The exact reasons for
this regional disparity should be analyzed in future
studies that consider ethnic-related factors, such as
heredity, and environmental exposures, such as geo-
graphic or cultural factors.
The risk of GC was higher in individuals with a positive
MN-FH of digestive cancers. A case–control study from
the USA found that the risk for GC patients was increased
by an MN-FH of digestive cancers, even after adjusting for
other risk factors, such as age, race, smoking and body
mass index (BMI) [16]. Another case–control study of GCpatients in Taiwan identified positive family history of GC
as a significant risk factor for GC [17]. Again, the MN-FH
risk determined by each of the studies using different
patient populations showed regional differences. A review
of the related literature indicated that the risk ratio was
higher in Asians than in Europeans [18]. Specifically,
the relative risk for GC in individuals with a positive
family history of GC varied from 1.5-fold to 3.5-fold,
compared with individuals with a negative family history
of GC [18]. Thus, it is not surprising that our study group
had unique profiles of organ-specific associated tumors
from MN-FH.
Colorectal and breast cancers are not common associated
tumors in GC patients
Colorectal cancer has been identified as a common associ-
ated tumor in MN-FH by previous studies of non-Chinese
GC patient populations. It ranked second among the
associated tumors reported by both the Italian study
(11.1%) [10] and the Japanese study (16%) [11]. In our
study population, however, only one of the 42 MN-FH-
associated tumors was colorectal cancer.
Breast cancer also ranked high (third place; 10.2%)
among the associated tumors in the Italian study [10].
In contrast, breast cancer ranked low (sixth place) in
the Japanese study, which found that only 4.3% of asso-
ciated tumors were breast cancers [11]. Our result was
consistent with the Japanese study, suggesting that some
Asian-specific factors may contribute to the MN-FH
risk of GC.
It is also possible that these results may simply reflect
the different incidences of colorectal cancer and breast
cancer in different regions [18]. It is well recognized that
incidences of colorectal cancer and breast cancer are
higher in Europe than in Japan or China. In addition,
European countries have a higher rate of hereditary diffuse
gastric cancer (HDGC) than Asian countries. HDGC
family history has been associated with breast cancer
[19,20], the etiology of which may involve germline
mutations in the cadherin-1 (CDH1) gene.
Prevalence of MN-FH does not correlate to GC patient
sex, age or histological subtype in Chinese patients
Similar to the Italian study [10], our results showed that
there was no correlation between prevalence of MN-FH
and sex of GC patients. Specifically, Bernini et al. reported
that there were no significant differences in sex among
patients with and without a family history of GC [10].
The study of GC patients by Lee et al. [21] also found
no differences among males and females in relation to
positive family history of cancer.
As for the putative relation with age, the Italian study
found no significant correlations between the GC patients
with and without a family history of GC (mean ages of
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findings. The Japanese study also found no correlation
with age (mean ages of patients with family history of
GC, with a family history of other cancers, and without
a family history of cancer were 64.4, 64.5 and 67.7
years, respectively) [11]. Finally, a comparative analysis
of familial and non-familial cancers in USA-based patients
found no significant difference in diagnostic age with
adenocarcinomas of the esophagus and the gastroesopha-
geal junction [22].
As for the putative relation between GC histological
subtypes and MN-FH, both our study and the Japanese
study [11] found no significant differences among GC
patients. However, an earlier Japanese study [23] did
report an increased risk of intestinal type GC when both
parents had GC (odds ratio = 7.8), and an increased risk
of diffuse-type cancer when both parents had non-GC
(odds ratio = 2.1). Intriguingly, the Italian study found
that the gastric adenocarcinoma type, as determined by
the Lauren classification system, was correlated to family
histories of GC [10]. Specifically, the patients with positive
family histories of GC were found to present with more
intestinal type GC than those with negative family histor-
ies of GC (71.8% vs. 55.1%, respectively).
Conclusions
More than one-third of the patients had at least one
first- or second-degree relative with a cancer diagnosis.
The majority of the associated tumors involved digestive
system organs, with the esophagus and stomach being
the most frequently represented, suggesting that a family
history of digestive system cancers may be a risk factor
for some GC patients. Colorectal and breast cancers,
which have been previously associated with an MN-FH
of GC in different ethnicities, were rare MN-FH types in
our study population. The MN-FH prevalence was not
correlated with patient sex, age or histological subtype.
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